Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use

Clinical Infectious Diseases

Volumn 55, Issue 4, 2012, Pages 543-550

  Sundar, Shyam ^a   Singh, Anup ^a   Rai, Madhukar ^a   Prajapati, Vijay K ^a   Singh, Avinash K ^a   Ostyn, Bart ^b   Boelaert, Marleen ^b   Dujardin, Jean Claude ^b,c   Chakravarty, Jaya ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MILTEFOSINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATEMESIS; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANCYTOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RIGOR; SCHOOL CHILD; SIDE EFFECT; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPROTOZOAL AGENTS; CHILD; COHORT STUDIES; FEMALE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84864488072     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis474     Document Type: Article

References (21)

1. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-3.
2. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Eng J Med 2002; 347:1739-46.
3. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-72.
4. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: E57-61.
5. Sundar S, Mondal D, Rijal S, et al. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal-The challenges for diagnosis and treatment. Trop Med Int Health 2008; 13:2-5.
6. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32:475-9.
7. Cancer Therapy Evaluation Program. Common toxicity criteria. Rockville, MD. National Cancer Institute, 2002. Available at: Http://ctep. cancer.gov/reporting/index.html. Accessed 7 October 2009.
8. Perez-Victoria FJ, Sanchez-Cañete MP, Seifert K, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat 2006; 9:26-39.
9. Rahman M, Ahmed BN, Faiz MA, et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kalaazar) in Bangladesh. Am J Trop Med Hyg 2011; 85:66-9.
10. Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis, 2000; 31:1110-3.
11. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22:434-8.
12. Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38:217-21.
13. Sundar S, Murray H. Availability of miltefosine for the treatment of kala-Azar in India. Bull World Health Organ 2005; 83:5.
14. Sundar S, Thakur BB, Tandon AK, et al. Clinicoepidemiological study of drug resistance in Indian kala-Azar. Br Med J 1994; 308:307.
15. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-12.
16. Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47:1000-6.
17. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial. Lancet 2011; 377:477-86.
18. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
19. Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007; 196:591-98.
20. Singh UK, Prasad R, Mishra OP, et al. Miltefosine in children with visceral leishmaniasis: A prospective, multicentric, crosssectional study. Indian J Pediatr 2006; 73:1077-80.
21. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate in treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43:357-64.